Specific immunotherapy targeting MN/CA9 tumor-associated antigen for renal cell carcinoma

针对肾细胞癌的 MN/CA9 肿瘤相关抗原的特异性免疫疗法

基本信息

  • 批准号:
    11671576
  • 负责人:
  • 金额:
    $ 2.5万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

MN/CA IX antigen is a plasma membrane glycoprotein expressed in several types of malignancies. Our previous study revealed that majority of renal cell carcinomas (RCC) express this antigen. We have synthesized 9mer antigen peptides and employed them as tumor vaccines to investigate the ability to induce this antiger specific responses. MN-RenCa and MN-3T3, MN/CA9 transfectant mouse renal cell carcinoma and embryofibroblast cell lines, have been established in our laboratory. Using these cell lines, we examined whether vaccination with the antigen peptides could induce specific CTL.Vaccines were made with HLA-A24 as well as H-2K^d restricted immunodominant peptides, and administrated into BALB/c mice with IFA every week. After the fourth vaccination, MN specific CTL activity was tested by TNF release assay and LDH release assay against MN-3T3. Furthermore, therapeutic efficacy of vaccination with the antigen peptides was investigated in syngeneic animal model. Spleen cells derived from BALB/c mouse vaccinated with antigen peptides showed reactivity against MN-RenCa and MN-3T3 cells, i.e., vaccination with MN antigen peptides resulted in the induction of MN specific CD8+ CTL precursor. This CTL precursor were transferred into naive mice after MN-RenCa inoculation and significantly low tumor-take was observed in these mice compared to control mice. These findings suggest that vaccination with MN antigen peptides may be potential therapeutic approach for RCC.
MN/CA IX抗原是在几种类型的恶性肿瘤中表达的质膜糖蛋白。我们以前的研究表明,大多数肾细胞癌(RCC)表达这种抗原。我们已经合成了9聚体抗原肽,并将其用作肿瘤疫苗来研究诱导这种抗原特异性反应的能力。本实验室建立了MN-RenCa和MN-3 T3、MN/CA_9转染小鼠肾细胞癌细胞系和胚胎成纤维细胞系。用HLA-A24和H-2K_d限制性免疫优势肽制备疫苗,每周免疫BALB/c小鼠,用IFA免疫。第四次接种后,通过TNF释放试验和LDH释放试验检测MN-3 T3的MN特异性CTL活性。此外,在同基因动物模型中研究了用抗原肽接种的治疗功效。来源于用抗原肽接种的BALB/c小鼠的脾细胞显示出对MN-RenCa和MN-3 T3细胞的反应性,即,用MN抗原肽接种导致MN特异性CD 8 + CTL前体的诱导。在MN-RenCa接种后将该CTL前体转移到幼稚小鼠中,并且与对照小鼠相比,在这些小鼠中观察到显著低的肿瘤摄取。这些结果表明,MN抗原肽疫苗可能是一种潜在的治疗RCC的方法。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
植村天受: "腎細胞癌の新しいバイオマーカーMN/CA9"臨床泌尿器科. 55(in press). (2001)
Tenke Uemura:“肾细胞癌的新生物标志物 MN/CA9”《临床泌尿学》55(出版中)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Cho M: "Activation of MN/CA9 gene in associated with hypomethylation in human renal cell carcinoma cell lines"Moleculan Cacinogenesis. 27(3). 184-189 (2001)
Cho M:“与人肾细胞癌细胞系低甲基化相关的 MN/CA9 基因激活”分子癌发生。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Uemura H: "MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas"British J.Cancer. 81. 741-746 (1999)
Uemura H:“MN/CA IX/G250 作为肾细胞癌免疫治疗的潜在靶点”British J.Cancer。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Uemura H: "MN/CA1X/G250 as a potential target for immunotherapy of renal cell carcinomas"British J.Cancer. 81(4). 741-746 (1999)
Uemura H:“MN/CA1X/G250 作为肾细胞癌免疫治疗的潜在靶点”British J.Cancer。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Uemura H: "MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas"British Journal of Cancer. 81(4). 741-746 (1999)
Uemura H:“MN/CA IX/G250 作为肾细胞癌免疫治疗的潜在靶点”英国癌症杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

UEMURA Hirotsugu其他文献

Randomized phase II trials of personalized peptide vaccination in advanced cancers
晚期癌症个性化肽疫苗接种的随机 II 期试验
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    ITO Kyogo;YUTANI Shigeru;SHICHIJO Sigeki;NOGUCHI Masanori;SASADA Tetsuro;YAMADA Akira;UEMURA Hirotsugu
  • 通讯作者:
    UEMURA Hirotsugu

UEMURA Hirotsugu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('UEMURA Hirotsugu', 18)}}的其他基金

Development of the HLA-A2 restricted multi-peptides vaccine for renal cell carcinoma.
肾细胞癌HLA-A2限制性多肽疫苗的研制。
  • 批准号:
    16H05466
  • 财政年份:
    2016
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of autophagy in PTEN/Atg7 double knockout mouse prostate cancer
PTEN/Atg7双敲除小鼠前列腺癌自噬功能分析
  • 批准号:
    26670707
  • 财政年份:
    2014
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Development of multi-peptide tumor vaccine for renal cell carcinoma
肾细胞癌多肽肿瘤疫苗的研制
  • 批准号:
    25293336
  • 财政年份:
    2013
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of tailor made peptide vaccines for renal cell carcinoma
开发针对肾细胞癌的定制肽疫苗
  • 批准号:
    22390305
  • 财政年份:
    2010
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of tailor-madepeptide vaccines for renal eell carcinoma
肾细胞癌定制肽疫苗的开发
  • 批准号:
    19390419
  • 财政年份:
    2007
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development new generation peptides derived from CA9 as tailar-made vaccines for renal cell carcinoma
开发新一代CA9衍生肽作为肾细胞癌定制疫苗
  • 批准号:
    16390468
  • 财政年份:
    2004
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
MN/CA9 expression and VHL regulation in renal cell carcinoma
肾细胞癌中MN/CA9的表达及VHL调控
  • 批准号:
    14571515
  • 财政年份:
    2002
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Active specific immunotherapy with MN\CA IX antigen peptide vaccines for renal cell carcinoma
MNCA IX 抗原肽疫苗主动特异性免疫治疗肾细胞癌
  • 批准号:
    13671671
  • 财政年份:
    2001
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular detection of circulating renal cell carcinoma cells by RT-PCR
RT-PCR对循环肾细胞癌细胞的分子检测
  • 批准号:
    09671643
  • 财政年份:
    1997
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Tools for active specific immunotherapy with anti-idiotype antibodies in human renal cell carcinoma
使用抗独特型抗体对人肾细胞癌进行主动特异性免疫治疗的工具
  • 批准号:
    07671748
  • 财政年份:
    1995
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
TASIS-花生(皮肤内靶向过敏原特异性免疫疗法)贴剂治疗花生过敏的安全性和耐受性
  • 批准号:
    10551184
  • 财政年份:
    2023
  • 资助金额:
    $ 2.5万
  • 项目类别:
SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.
筛选耐受性佐剂以增强乳糜泻的抗原特异性免疫治疗。
  • 批准号:
    10933263
  • 财政年份:
    2023
  • 资助金额:
    $ 2.5万
  • 项目类别:
Immunological analysis and POC establishment of comprehensive neoantigen-specific immunotherapy for cold tumor
冷肿瘤新抗原特异性免疫综合治疗的免疫学分析及POC建立
  • 批准号:
    23H03780
  • 财政年份:
    2023
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Modeling Dynamic Immune Cell Modulation in a 3-D Tissue Engineered Platform to Enhance Patient-specific Immunotherapy for Lung Cancer
在 3D 组织工程平台中模拟动态免疫细胞调节,以增强肺癌患者特异性免疫治疗
  • 批准号:
    10518637
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
Modeling Dynamic Immune Cell Modulation in a 3-D Tissue Engineered Platform to Enhance Patient-specific Immunotherapy for Lung Cancer
在 3D 组织工程平台中模拟动态免疫细胞调节,以增强肺癌患者特异性免疫治疗
  • 批准号:
    10672244
  • 财政年份:
    2022
  • 资助金额:
    $ 2.5万
  • 项目类别:
Tolerising antigen-specific immunotherapy for type 1 diabetes
1 型糖尿病的耐受性抗原特异性免疫疗法
  • 批准号:
    nhmrc : 2002917
  • 财政年份:
    2021
  • 资助金额:
    $ 2.5万
  • 项目类别:
    Ideas Grants
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
基于微针的靶向过敏原特异性免疫疗法治疗花生过敏
  • 批准号:
    10368182
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
基于微针的靶向过敏原特异性免疫疗法治疗花生过敏
  • 批准号:
    9899934
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
Microneedle Based Targeted Allergen Specific Immunotherapy for Treatment of Peanut Allergies
基于微针的靶向过敏原特异性免疫疗法治疗花生过敏
  • 批准号:
    10407661
  • 财政年份:
    2019
  • 资助金额:
    $ 2.5万
  • 项目类别:
IL-15 TRiKES-based specific immunotherapy of TNBC; resistance mechanisms
基于IL-15 TRiKES的TNBC特异性免疫治疗;
  • 批准号:
    9751815
  • 财政年份:
    2018
  • 资助金额:
    $ 2.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了